KYTX — Kyverna Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1994702 ·
Last close
$4.70
Market Cap
$297.14M
52W High
$13.67
52W Low
$4.49
ADV30
843,714
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -42,899,000 | -41,941,000 | 189,437,000 | 31,818,000 | 56,283,000 |
| Jun 2026 | 0 | — | -39,556,000 | -38,319,000 | 219,823,000 | 31,806,000 | 54,274,000 |
| Mar 2026 | 0 | — | -41,367,000 | -39,728,000 | 257,024,000 | 32,194,000 | 61,444,000 |
| Dec 2025 | 0 | — | -39,282,000 | -37,804,000 | 293,826,000 | 124,093,000 | 61,550,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-150,797,000
Investing CF
$-2,835,000
Financing CF
$151,286,000
CapEx
$-1,454,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.77
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-544,815,000
Inventory
—
Receivables
—
ST Investments
$138,754,000
EBIT TTM
$-155,279,000
Pretax Income TTM
$-157,792,000
Interest Exp TTM
$2,513,000
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -169,827,000 | -161,307,000 | 293,826,000 | 61,550,000 | 232,276,000 | -153,712,000 |
| Dec 2024 | 0 | -142,604,000 | -127,477,000 | 304,645,000 | 38,058,000 | 266,587,000 | -114,250,000 |
| Dec 2023 | 0 | -62,406,000 | -60,366,000 | 75,195,000 | 206,592,000 | -131,397,000 | -52,410,000 |
| Dec 2022 | 7,025,000 | -29,384,000 | -28,893,000 | 66,924,000 | 140,921,000 | -73,997,000 | -36,113,000 |
TTM Snapshot
Revenues TTM
$8,161,000
NetIncome TTM
$-152,638,000
OpCashFlow TTM
—
Assets (Latest)
$219,823,000
Forward EPS
$-3.04
Max Pain — expiry 2027-03-19
max pain strike: $7.50 · spot: $4.48 · call oi: 1,176 · put oi: 3,522
Expected Move to 2027-03-19:
±$2.63
(58.71%) —
implied range
$1.85 –
$7.11
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SCTX | Scribe Therapeutics, Inc. | $298.64M | $15.77 | — |
| AGMB | AgomAb Therapeutics NV | $291.55M | $5.92 | — |
| AUTL | Autolus Therapeutics plc | $290.12M | $1.09 | — |
| EDIT | Editas Medicine, Inc. | $281.67M | $1.83 | — |
| AGEN | AGENUS INC | $280.98M | $6.21 | — |
News headlines (Yahoo Finance, 1h cache)
Kyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial Results
2026-11-12 13:00 · Yahoo
Kyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA Neurology
2026-11-09 16:00 · Yahoo
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
2026-11-05 21:02 · Yahoo
Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto
2026-10-21 11:15 · Yahoo
KYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data — But CEO Says Disease Burden Justifies A Premium Price
2026-09-24 18:28 · Yahoo
Kyverna stock jumps on positive one-year therapy data
2026-09-24 14:05 · Yahoo
Kyverna Reports One-Year Miv-Cel Data From SPS and gMG Trials
2026-09-24 10:39 · Yahoo
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
2026-09-24 10:00 · Yahoo
Kyverna Therapeutics to Present at Upcoming Investor Conferences
2026-09-02 20:05 · Yahoo
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
2026-09-02 12:32 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.